23 of 23 indicators shown
| FY25-26 Q2 | FY25-26 Q3 | FY25-26 Q4 | FY26-27 Q1 | FY26-27 Q2 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical Quality & Outcomes | ||||||||||||||||||
| Cervical cancer screening up-to-date rate | Attention | 66.6% | 82% | 15.4 pp below | 64.1% | 64.5% | 64.5% | 64.3% | 64.4% | 65.9% | 66.3% | 66.6% | 64.9% | 63.0% | 61.6% | 60.1% | 60.1% | 25 below (100%) |
| Heart failure: ACE inhibitor or ARB prescribed | Attention | 72.8% | 80% | 7.2 pp below | 72.2% | 72.2% | 72.2% | 72.2% | 72.2% | 72.2% | 72.0% | 72.8% | 68.5% | 64.1% | 59.1% | 52.9% | 52.9% | 23 below (92%) |
| Polypharmacy medication review (10+ medications) | Attention | 44.9% | 50% | 5.1 pp below | 45.4% | 45.2% | 44.9% | 44.8% | 44.8% | 44.3% | 44.4% | 44.9% | 40.9% | 37.1% | 33.0% | 29.1% | 29.1% | 17 below (68%) |
| Hypertension: BP measured and at target | Watch | 62.8% | 65% | 2.2 pp below | 61.2% | 61.4% | 61.4% | 61.2% | 61.3% | 61.3% | 61.5% | 62.8% | 52.9% | 43.6% | 35.6% | 28.2% | 28.2% | 14 below (56%) |
| Mammogram up-to-date rate | Watch | 68.0% | 70% | 2.0 pp below | 61.7% | 61.8% | 62.1% | 62.4% | 63.3% | 66.2% | 66.9% | 68.0% | 65.1% | 62.4% | 58.4% | 55.1% | 55.1% | 10 below (43%) |
| Diabetes: HbA1c tested (≥2 in 12 months) | Watch | 69.6% | 70% | 0.4 pp below | 66.8% | 69.0% | 68.3% | 68.6% | 70.2% | 68.9% | 68.7% | 69.6% | 64.5% | 59.5% | 54.3% | 46.2% | 46.2% | 14 below (56%) |
| Diabetes: Statin prescribed (age ≥40) | On track | 75.0% | 75% | at target | 71.4% | 71.7% | 71.8% | 72.4% | 73.2% | 73.3% | 73.2% | 75.0% | 69.5% | 63.0% | 57.2% | 49.7% | 49.7% | 13 below (52%) |
| Influenza immunization rate (age 65+) | On track | 70.0% | 70% | at target | 65.0% | 65.5% | 65.7% | 67.0% | 67.7% | 68.4% | 68.7% | 70.0% | 64.6% | 59.5% | 54.7% | 49.0% | 49.0% | 13 below (52%) |
| Diabetes: mean HbA1c (mmol/mol) | On track | 52.3 mmol/mol | 53 mmol/mol | 0.7 mmol/mol below | 53.7 mmol/mol | 53.6 mmol/mol | 53.5 mmol/mol | 53.4 mmol/mol | 53.1 mmol/mol | 52.9 mmol/mol | 52.5 mmol/mol | 52.3 mmol/mol | 52.2 mmol/mol | 52.2 mmol/mol | 52.2 mmol/mol | 52.2 mmol/mol | 52.2 mmol/mol | 9 above (36%) |
| Colorectal screening up-to-date (FIT, colonoscopy, or sigmoidoscopy) | On track | 67.5% | 65% | 2.5 pp above | 65.2% | 65.1% | 65.2% | 65.1% | 65.0% | 67.2% | 67.1% | 67.5% | 66.2% | 65.1% | 64.0% | 62.9% | 62.9% | 12 below (48%) |
| Diabetes: Retinal exam (≥1 in 24 months) | On track | 68.0% | 65% | 3.0 pp above | 64.4% | 64.7% | 64.9% | 65.8% | 66.0% | 66.5% | 67.0% | 68.0% | 65.2% | 62.4% | 60.0% | 57.3% | 57.3% | 8 below (32%) |
| Colorectal cancer screening up-to-date rate | On track | 69.0% | 65% | 4.0 pp above | 62.2% | 62.1% | 62.9% | 63.5% | 63.9% | 67.2% | 67.8% | 69.0% | 66.6% | 64.3% | 61.8% | 58.8% | 58.8% | 9 below (36%) |
| Patient Experience & Access | ||||||||||||||||||
| Low-acuity ED visits (per 1,000) | Attention | 50 per 1,000 | 25 per 1,000 | 25 per 1,000 above | 50 per 1,000 | 49 per 1,000 | 49 per 1,000 | 49 per 1,000 | 50 per 1,000 | 49 per 1,000 | 49 per 1,000 | 50 per 1,000 | 46 per 1,000 | 41 per 1,000 | 37 per 1,000 | 35 per 1,000 | 35 per 1,000 | 23 above (92%) |
| Same- or next-day appointment access rate | Attention | 55.2% | 60% | 4.8 pp below | 52.5% | 52.8% | 53.0% | 53.2% | 53.6% | 54.0% | 54.2% | 55.2% | 50.7% | 46.8% | 42.2% | 37.0% | 37.0% | 18 below (72%) |
| 3rd-next-available appointment (days) | Attention | 6.0 days | 5 days | 1.0 days above | 6.7 days | 6.6 days | 6.4 days | 6.3 days | 6.0 days | 6.0 days | 6.1 days | 6.0 days | 6.0 days | 6.0 days | 6.0 days | 6.0 days | 6.0 days | 20 above (80%) |
| Post-discharge follow-up within 7 days | On track | 62.8% | 60% | 2.8 pp above | 59.2% | 59.5% | 59.8% | 60.3% | 60.7% | 61.3% | 61.5% | 62.8% | 57.7% | 53.0% | 47.9% | 42.6% | 42.6% | 10 below (40%) |
| Efficiency & Value | ||||||||||||||||||
| ED visits for ambulatory-care-sensitive conditions (per 1,000) | Critical | 46 per 1,000 | 20 per 1,000 | 26 per 1,000 above | 46 per 1,000 | 46 per 1,000 | 46 per 1,000 | 46 per 1,000 | 46 per 1,000 | 46 per 1,000 | 45 per 1,000 | 46 per 1,000 | 43 per 1,000 | 38 per 1,000 | 34 per 1,000 | 29 per 1,000 | 29 per 1,000 | 25 above (100%) |
| 30-day hospital readmissions (per 1,000) | Attention | 24 per 1,000 | 15 per 1,000 | 9 per 1,000 above | 23 per 1,000 | 23 per 1,000 | 23 per 1,000 | 23 per 1,000 | 23 per 1,000 | 24 per 1,000 | 24 per 1,000 | 24 per 1,000 | 22 per 1,000 | 20 per 1,000 | 17 per 1,000 | 16 per 1,000 | 16 per 1,000 | 17 above (68%) |
| Generic prescribing rate | On track | 82.6% | 75% | 7.6 pp above | 79.4% | 79.5% | 80.2% | 80.2% | 80.5% | 80.9% | 81.1% | 82.6% | 75.7% | 69.1% | 62.3% | 55.7% | 55.7% | 2 below (8%) |
| Health Equity | ||||||||||||||||||
| Cervical screening rate gap (by deprivation band) | Attention | 13.5 pp | 10 pp | 3.5 pp above | 11.5 pp | 10.6 pp | 12.1 pp | 12.1 pp | 10.9 pp | 14.2 pp | 14.9 pp | 13.5 pp | 13.9 pp | 13.5 pp | 12.2 pp | 10.3 pp | 10.3 pp | 7 above (70%) |
| Influenza immunization rate gap (by deprivation band) | On track | 1.8 pp | 10 pp | 8.2 pp below | 5.2 pp | 5.2 pp | 6.9 pp | 8.6 pp | 7.1 pp | 0.7 pp | 3.1 pp | 1.8 pp | 1.8 pp | 1.8 pp | 1.8 pp | 1.8 pp | 1.8 pp | 1 above (20%) |
| Diabetes HbA1c testing rate gap (by deprivation band) | On track | 0.0 pp | 10 pp | 10.0 pp below | 3.1 pp | 3.1 pp | 3.1 pp | 0.0 pp | 0.0 pp | 0.0 pp | 0.0 pp | 0.0 pp | 0.0 pp | 0.0 pp | 0.0 pp | 0.0 pp | 0.0 pp | 0 above (0%) |
| Colorectal screening rate gap (by deprivation band) | On track | -0.4 pp | 10 pp | 10.4 pp below | 1.7 pp | 1.7 pp | 1.7 pp | 1.7 pp | 1.7 pp | 0.8 pp | -0.1 pp | -0.4 pp | -0.4 pp | -0.4 pp | -0.4 pp | -0.4 pp | -0.4 pp | 4 above (29%) |